Arcus Biosciences (RCUS) Accounts Payables (2017 - 2026)

Arcus Biosciences' Accounts Payables history runs 10 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 77.27% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (up 77.27% YoY), while the FY2025 annual figure was $42.0 million, up 133.33% from the prior year.
• Accounts Payables for Q1 2026 stood at $39.0 million, down from $42.0 million in the prior quarter.
• The five-year high for Accounts Payables was $42.0 million in Q3 2025, with the low at $10.5 million in Q3 2022.
• The 5-year median for Accounts Payables is $18.1 million (2022), against an average of $22.4 million.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables tumbled 45.41% in 2023, then surged 223.08% in 2025.
• Arcus Biosciences' Accounts Payables stood at $20.0 million in 2022, then fell by 15.0% to $17.0 million in 2023, then advanced by 5.88% to $18.0 million in 2024, then soared by 133.33% to $42.0 million in 2025, then retreated by 7.14% to $39.0 million in 2026.
• Business Quant data shows RCUS's Accounts Payables at $39.0 million in Q1 2026, $42.0 million in Q4 2025, and $42.0 million in Q3 2025.